The bridge is already built: management walks investors from today's numbers to a bigger business using only pieces alre
The model's full reasoning — Q2 2023 call → NO我们根据提供的财报电话会议记录,判断管理层对明年业务前景的说明是否主要由已确定且已在进行中的具体部分构成,而非市场希望、管道或一般需求。管理层提到了KEDRAB分销协议延长至2026年,以及正在进行的讨论;CYTOGAM技术转移已获FDA和Health Canada批准,预计第四季度开始销售;血浆采集中心扩张,第二中心2024年初开业;InnovAATe试验已入组62名患者,EMA确认设计,FDA讨论计划年底进行;FIMI投资待股东批准。这些部分中,KEDRAB协议已延长,CYTOGAM生产已获批,血浆中心扩张已计划,但InnovAATe试验是开发阶段,FIMI投资尚待批准。管理层重申2023年指引,并预期下半年增长。但整体上,管理层提到的具体部分如KEDRAB、CYTOGAM、血浆中心都是已确定或已在进行中的,且贡献将在未来一年内体现。然而,这些部分是否足以构成“业务已锁定”的实质性增长?管理层强调KEDRAB需求增加,CYTOGAM即将销售,但未明确量化这些部分对整体业务的提升。此外,FIMI投资尚待批准,不算已确定。InnovAATe是长期机会。因此,管理层的前景描述更多基于现有业务的增长动力,而非明确已锁定的新合同或资产。但KEDRAB协议延长和CYTOGAM生产转移是已确定的,且贡献即将开始。不过,这些是否“material together”?管理层重申指引,但未明确说这些部分使当前数字低估。因此,可能更接近NO,因为主要依赖市场增长和需求。但管理层明确提到KEDRAB需求增加和CYTOGAM即将销售,这些是已确定的。权衡后,我认为答案是NO,因为管理层没有明确表示这些部分使当前业绩低估,而是强调增长趋势。但根据问题标准,如果管理层提到已签约的合同和已获批的生产,且贡献即将开始,可能算YES。但需要看是否“material together”。管理层提到KEDRAB销售增长显著,CYTOGAM技术转移完成,这些是具体且已确定的。但未量化。我认为更符合YES,因为管理层明确提到这些已确定的项目。但注意,KEDRAB协议延长是现有协议的延续,不是新增长。CYTOGAM是已有产品,只是生产转移。血浆中心是扩张。这些可能只是常规业务。因此,我倾向于NO。最终答案:NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| KNDI | Kandi Technologies Group, Inc. | Q2 2021 | 2021-08-09 | F |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| XOM | Exxon Mobil Corporation | Q2 2018 | 2018-07-27 | C |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| ACCO | ACCO Brands Corporation | Q1 2016 | 2016-04-27 | B+ |
EVGO · Q2 2022 → YESThe question is about whether management's explanation of the next year's business is built primarily from specific pieces already secured or in motion, making current results understate the locked-in...YES The transcript shows management framing the next-year outlook around the newly announced, signed GM-Pilot eXtend deal (up to 2,000 stalls at 500 locations, with EVgo procuring, constructing, operating, and maintaining, delivering both near-term revenue and longer-term contracted cash flows that already exceed IRR hurdles) plus the Delta supply agreement (1,000+ chargers for 2,000 stalls through 2026) and the GSA BPA (which removes procurement friction for federal fleets). These pieces are presented as already committed and in motion, with explicit timing for revenue ramp in H2 2022 and into 202 3, while the company notes it has baked some of the PFJ contribution into its 2022 guidance. The structure treats these secured elements as the primary bridge from today’s numbers to a meaningfully larger business, rather than relying on pipeline, demand, or future bids. Other items (NEVI solicitations, fleet pilots ) are secondary and contingent, but the core forward posture is built on the named, already-executed contracts and programs. Current results visibly understate the locked-in trajectory because the eXtend model shifts cash flows forward and the secured stalls/contracts are only beginning to flow.
BRBR · Q4 2023 → YESThe question is about whether management's explanation of the next year's business is built primarily from specific pieces already secured or in motion, such that current results understate the locked...YES The transcript shows management framing fiscal '24 growth as driven by concrete, already-committed pieces: the two co-man additions from '23 that are scaling, the Michael Foods greenfield facility that starts up in December and will be a "much larger contributor" in the second half of '24, the 20 %+ production growth plan (40 % from new co-mans in '24, 40 % from lapping prior adds, 20 % from existing), and the restart of shake promotions in Q2 plus marketing step-up in Q4 once target weeks of supply are reached. These are presented as nameable, scheduled 2024 actions that will enable double-digit volume growth for both Premier Protein and Dymatize, with the current-year results (22 % sales growth under capacity constraints) treated as a base that the locked-in capacity ramp will visibly outgrow.
MEC · Q3 2022 → YESThe question is about whether management's explanation of the next year's business is built primarily from specific pieces already secured or in motion, such that current results understate the locked...YES The transcript shows management framing 2023 growth primarily around specific, already secured or in-motion pieces: the electric side-by-side family of parts (production fully launching in 2023), the reshoring project for the commercial vehicle customer (production scheduled to start early 2023), the high-value ag takeover project (already awarded), incremental business on the light-duty truck platform, and the new industrial infrastructure customer relationship (quickly supported and expected to grow). These are presented as nameable, committed items whose contributions are beginning or ramping over the coming year.